Molecular Signatures in Inflammatory Skin Disease

Launched by PROF. DR. STEPHAN WEIDINGER · Nov 29, 2017

Keywords

ClinConnect Summary

This clinical trial, titled "Molecular Signatures in Inflammatory Skin Disease," is looking at how different biological factors affect conditions like atopic dermatitis and psoriasis. The researchers aim to better understand these skin diseases by collecting detailed information from patients over time, especially after they receive specific treatments. By analyzing this information, they hope to discover patterns that could help guide future treatments and improve patient care.

To participate in this trial, you need to have a diagnosis of chronic psoriasis or atopic dermatitis and meet certain severity scores. Eligible participants will be those who can provide written consent and are currently receiving treatment with biologic medications as part of their regular care. During the study, participants can expect to undergo several assessments to collect clinical and molecular data, which will help researchers gain insights into the diseases. It's important to note that certain recent treatments may exclude individuals from participating, so be sure to discuss your medical history with the study team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide written informed consent and comply with the protocol
• • Dermatologist-diagnosed chronic inflammatory skin disease
• • Subject receives systemic therapy within routine care (in-label use of biologics)
• Exclusion Criteria:
• • Subject is unable to provide written informed consent or comply with the protocol.
• • Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit.
• • Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.